Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
AstraZeneca
McKesson
Colorcon
Johnson and Johnson

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Teva Pharms Usa Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS USA, and what generic alternatives to TEVA PHARMS USA drugs are available?

TEVA PHARMS USA has one hundred and sixty approved drugs.

There are five US patents protecting TEVA PHARMS USA drugs. There are twenty-six tentative approvals on TEVA PHARMS USA drugs.

There are sixty-nine patent family members on TEVA PHARMS USA drugs in thirty-two countries and four hundred and seventy-one supplementary protection certificates in sixteen countries.

Summary for Teva Pharms Usa
International Patents:69
US Patents:5
Tradenames:139
Ingredients:136
NDAs:160

Drugs and US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 073303-001 Oct 31, 1991 DISCN No No   Start Trial   Start Trial
Teva Pharms Usa DOCETAXEL docetaxel INJECTABLE;INJECTION 203877-002 Sep 16, 2015 DISCN No No   Start Trial   Start Trial
Teva Pharms Usa METHYLPREDNISOLONE ACETATE methylprednisolone acetate INJECTABLE;INJECTION 040620-001 Oct 27, 2006 AB RX No No   Start Trial   Start Trial
Teva Pharms Usa LINEZOLID linezolid TABLET;ORAL 078061-001 May 18, 2015 AB RX No No   Start Trial   Start Trial
Teva Pharms Usa IFOSFAMIDE/MESNA KIT ifosfamide; mesna INJECTABLE;INTRAVENOUS 075874-002 Feb 26, 2002 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,620,847   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 6,362,161   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 7,199,098   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 5,981,589   Start Trial
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 8,367,605   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26

Supplementary Protection Certificates for Teva Pharms Usa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746976 1790033-3 Sweden   Start Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008
2487166 93354 Luxembourg   Start Trial PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ALAFENAMIDE DE TENOFOVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE D'ALAFENAMIDE DE TENOFOVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1061
0564409 SPC/GB02/016 United Kingdom   Start Trial PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108
0961612 2009C/046 Belgium   Start Trial PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111
0914118 C00914118/01 Switzerland   Start Trial PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Medtronic
Johnson and Johnson
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.